MedTrace Logo

Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment

NCT05774990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 621

Last updated 2026-05-14

No results posted yet for this study

Summary

The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark. The study will be a retrospective nationwide survey study of all children who received first-line chemotherapy for acute leukemia from 2008 to 2022 in Danish pediatric oncology units. The study population includes 621 children under the age of 18. Data will be collected from medical records, hospital databases, and national databases. When the IMI subgroup has been identified, this will be compared to the leukemic group that did not develop IMI. Statistical analysis can then determine the occurrence, mortality rate, and possible IMI risk factors.

Conditions

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Odense Patient Data Explorative Network

    collaborator OTHER

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Rasmus Møller Duus, MD · University of Southern Denmark

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-10-26
Completion
2025-10-26

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05774990 on ClinicalTrials.gov